PhaseRx, a Seattle-based biotech startup focused on delivering therapies via sIRNA, has raised $19 million in first-round funding. Backers include 5AM Ventures, Arch Venture Partners and Versant Ventures. The company was founded by Robert Overall, a former general partner with Frazier Healthcare Ventures. Get more info.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.